Moleculin Biotech (NASDAQ:MBRX) Raised to “Buy” at HC Wainwright
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was upgraded by equities research analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Monday, MarketBeat.com reports. The firm presently has a $4.00 target price on the stock. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2025 earnings at ($0.39) […]
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was upgraded by equities research analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Monday, MarketBeat.com reports. The firm presently has a $4.00 target price on the stock. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2025 earnings at ($0.39) […]
